820 related articles for article (PubMed ID: 19053049)
1. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
[TBL] [Abstract][Full Text] [Related]
2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
3. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
[TBL] [Abstract][Full Text] [Related]
4. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
5. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.
Harrison SA; Fincke C; Helinski D; Torgerson S; Hayashi P
Aliment Pharmacol Ther; 2004 Sep; 20(6):623-8. PubMed ID: 15352910
[TBL] [Abstract][Full Text] [Related]
7. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
9. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
Kiortsis DN; Tsouli S; Filippatos TD; Konitsiotis S; Elisaf MS
Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
[TBL] [Abstract][Full Text] [Related]
10. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
Svendsen M; Helgeland M; Tonstad S
J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
[TBL] [Abstract][Full Text] [Related]
11. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
12. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
13. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
14. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
[TBL] [Abstract][Full Text] [Related]
17. Weight loss as a treatment for nonalcoholic fatty liver disease.
Clark JM
J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S39-43. PubMed ID: 16540766
[TBL] [Abstract][Full Text] [Related]
18. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
[TBL] [Abstract][Full Text] [Related]
19. Orlistat for obesity: benefits beyond weight loss.
Hsieh CJ; Wang PW; Liu RT; Tung SC; Chien WY; Chen JF; Chen CH; Kuo MC; Hu YH
Diabetes Res Clin Pract; 2005 Jan; 67(1):78-83. PubMed ID: 15620437
[TBL] [Abstract][Full Text] [Related]
20. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band.
Zoss I; Piec G; Horber FF
Obes Surg; 2002 Feb; 12(1):113-7. PubMed ID: 11868286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
